Condition: Stress · Sponsor: dsm-firmenich Switzerland AG
The placebo-controlled, double blind parallel intervention trial "PostWelLB" aims to test whether 3 months of daily supplementation with the postbiotic product "Humiome® Post LB" (HPLB; 340 mg / day) can reduce self-reported stress (PSS10 questionnaire)- in an older (50 - 75 years; all genders) population in France.
This description comes directly from the study's public registry record.
Eleonora Rossi, PhD · +33 240205799 · eleonora.rossi@biofortis.fr
Erik Eckhardt, PhD · +33 659328475 · erik.eckhardt@dsm-firmenich.com
Always discuss trial participation with your own doctor first.
| Biofortis | Saint-Herblain, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07471659